Promising Cystic Fibrosis Compound On Track For Development
Gilead Sciences, Inc., one of the world’s largest biopharmaceutical companies, and Parion Sciences, Inc., a development-stage pharmaceutical company, announced they will co-develop Parion 680, a compound that could become an important new drug in treating the basic defect in cystic fibrosis. This product was identified as part of a $1.7 million award to Parion from Cystic Fibrosis Foundation Therapeutics, Inc.-the CF Foundation’s nonprofit drug discovery and development affiliate.
